Home › New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
 

Keywords :   


New KEYTRUDA (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer

2016-05-16 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 7, 2016. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Kim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in well data updated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
11.05YouGov Unveils Americans Skincare Routines
11.05Naples Soap Company Reports Revenue Surge Amidst Tourist Season
11.05Indian Perfume Brand Eze Perfumes Enters US Market
11.05LOccitane Travel Retail Showcases Travel Retail Brand Portfolio at TFWA Asia Pacific
10.05How crops are being disaster-proofed
10.05'I got married on a Thursday and saved 3,000'
10.05Inland Packaging receives Molson Coors Packaging Supplier of the Year
10.05Delays warning as M25 stretch closes for the weekend
More »